Generic Name and Formulations:
Ciclesonide 37mcg/actuation; metered-dose nasal aerosol; contains HFA.
Indications for ZETONNA:
Treatment of symptoms associated with seasonal and perennial allergic rhinitis.
One actuation in each nostril once daily (37mcg/actuation); max 74mcg/day.
Conduct nasal examination before starting treatment. Discontinue if nasal erosion, ulceration, or perforation occurs. Active or quiescent respiratory tract tuberculosis. Infections (eg, fungal, bacterial, viral, parasitic, or ocular herpes simplex). If exposed to measles or chickenpox, consider immunoglobulin prophylactic therapy. Monitor for acute adrenal insufficiency if prolonged systemic corticosteroid therapy is replaced with topical steroids. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and for candida infection and other nasal cavity changes. Monitor for growth suppression in children. Monitor for vision changes or in those with a history of increased intraocular pressure, glaucoma or cataracts. Avoid spraying in eyes or directly onto the nasal septum. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by ketoconazole.
Nasal discomfort, headache, epistaxis; nasal ulceration, nasal septal perforation, candida infection, impaired wound healing.
Nasal aerosol—6.1g (60 actuations)
Renal and Urology News Articles
- Urine Immunoassay Identifies Novel Lupus Nephritis Biomarkers
- Novel Albuminuria Endpoints May Improve CKD Progression Trials
- Comorbidities Adversely Linked to Cancer Trial Participation
- Global Demand for Bladder Cancer Treatment Threatens Supply in 2019
- Opioids Now More Deadly for Americans Than Traffic Accidents
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)